Shandong Sito Bio-technology Co Ltd Total Liabilities
Shandong Sito Bio-technology Co Ltd total liabilities. Based on the latest financial reports, Shandong Sito Bio-technology Co Ltd (300583) has total liabilities worth CN¥1.16 Billion CNY (≈ $169.59 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Shandong Sito Bio-technology Co Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Shandong Sito Bio-technology Co Ltd (2012–2025)
Total liabilities of Shandong Sito Bio-technology Co Ltd from 2012 to 2025. This chart illustrates how Shandong Sito Bio-technology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Shandong Sito Bio-technology Co Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
Shandong Sito Bio-technology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shandong Sito Bio-technology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gogo Inc
NASDAQ:GOGO
|
USA | $1.12 Billion |
|
Palmer Square Capital BDC Inc.
NYSE:PSBD
|
USA | $726.43 Billion |
|
Planet Technology
TWO:6263
|
Taiwan | NT$996.26 Million |
|
Rana Gruber AS
OL:RANA
|
Norway | Nkr783.91 Million |
|
Yaxing Chem
SHG:600319
|
China | CN¥2.64 Billion |
|
Shenke Slide Bearing Corp
SHE:002633
|
China | CN¥374.40 Million |
|
Blend Labs Inc
NYSE:BLND
|
USA | $217.17 Million |
|
Transcontinental Inc
TO:TCL-A
|
Canada | CA$815.10 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Shandong Sito Bio-technology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Shandong Sito Bio-technology Co Ltd (300583) total assets.
Liquidity & Leverage Metrics
Shandong Sito Bio-technology Co Ltd Total Liabilities Ratios Explained
Shandong Sito Bio-technology Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shandong Sito Bio-technology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shandong Sito Bio-technology Co Ltd (2012–2025)
The table below shows the annual total liabilities of Shandong Sito Bio-technology Co Ltd from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.16 Billion ≈ $169.59 Million |
+1.52% |
| 2024-12-31 | CN¥1.14 Billion ≈ $167.06 Million |
-2.82% |
| 2023-12-31 | CN¥1.17 Billion ≈ $171.91 Million |
-4.04% |
| 2022-12-31 | CN¥1.22 Billion ≈ $179.15 Million |
-1.09% |
| 2021-12-31 | CN¥1.24 Billion ≈ $181.11 Million |
+7.63% |
| 2020-12-31 | CN¥1.15 Billion ≈ $168.27 Million |
+4.49% |
| 2019-12-31 | CN¥1.10 Billion ≈ $161.04 Million |
+50.21% |
| 2018-12-31 | CN¥732.63 Million ≈ $107.21 Million |
+130.81% |
| 2017-12-31 | CN¥317.42 Million ≈ $46.45 Million |
-4.74% |
| 2016-12-31 | CN¥333.22 Million ≈ $48.76 Million |
+0.48% |
| 2015-12-31 | CN¥331.62 Million ≈ $48.53 Million |
+53.30% |
| 2014-12-31 | CN¥216.31 Million ≈ $31.65 Million |
+93.44% |
| 2013-12-31 | CN¥111.83 Million ≈ $16.36 Million |
+306.45% |
| 2012-12-31 | CN¥27.51 Million ≈ $4.03 Million |
-- |
About Shandong Sito Bio-technology Co Ltd
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, bis-decyl alcohol (BA), neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, 16ß and 16… Read more